The 1995 Walter Hubert Lecture - Molecular epidemiology of human cancer: Insights from the mutational analysis of the p53 tumour-suppressor gene

British Journal of Cancer

Volumn 73, Issue 3, 1996, Pages 261-269

  Harris, C C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Aflatoxin B1; Cancer risk assessment; Cancer susceptibility genes; Liver cancer; Skin cancer; Ultraviolet light

Indexed keywords

PROTEIN P53;

CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; DNA REPAIR; EPIDEMIOLOGY; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0030043019     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.47     Document Type: Review

References (84)

1. AGUILAR F, HUSSAIN SP AND CERUTTI P. (1993). Aflatoxin B1 induces the transversion of G → T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl Acad. Sci. USA, 90, 8586-8590.
2. AGUILAR F, HARRIS CC, SUN T, HOLLSTEIN M AND CERUTTI P. (1994). Geographic variation of p53 mutational profile in nonmalignant human liver. Science, 264, 1317-1319.
3. BAKALIN G, YAKOVLEVA T, SELIVANOVA G, MAGNUSSON KP, SZEKELY L, KISELEVA E, KLEIN G, TERENIUS L AND WIMAN KG. (1994). p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc. Natl Acad. Sci. USA, 91, 413-417.
4. BAKER SJ, MARKOWITZ S, FEARON ER, WILLSON JK AND VOGELSTEIN B. (1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. Science, 249, 912-915.
5. BARRETT JC AND WISEMAN RW. (1992). Molecular carcinogenesis in humans and rodents. Prog. Clin. Biol. Res. 376, 1-30.
6. BENN J AND SCHNEIDER RJ. (1994). Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc. Natl Acad. Sci. USA, 91, 10350-10354.
7. BRASH DE, RUDOLPH JA, SIMON JA, LIN A, MCKENNA GJ, BADEN HP, HALPERIN AJ AND PONTEN J. (1991). A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl Acad. Sci. USA, 88, 10124-10128.
8. BRENNAN JA, BOYLE JO, KOCH WM, GOODMAN SN, HRUBAN RH, EBY YJ, COUCH MJ, FORASTIERE AA AND SIDRANSKY D. (1995). Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 332, 712-717.
9. BRESSAC B, KEW M, WANDS J AND OZTURK M. (1991). Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature, 350, 429-431.
10. CARIELLO NF, CUI L, BEROUD C AND SOUSSI T. (1994). Database and software for the analysis of mutations in the human p53 gene. Cancer Res., 54, 4454-4460.
11. CASELMANN WH, MEYER M, KEKULE AS, LAUER U, HOFSCHNEIDER PH AND KOSHY R. (1990). A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA. Proc. Natl Acad. Sci. USA, 87, 2970-2974.
12. CHEN PL, CHEN Y, BOOKSTEIN R AND LEE WH. (1991). Genetic mechanisms of tumor suppression by the human p53 gene. Science, 250, 1576-1580.
13. CHO Y, GORINA S, JEFFREY P AND PAVLETICH NP. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: A framework for understanding how mutations inactivate p53. Science, 265, 346-355.
14. CLORE GM, OMICHINSKI JG, SAKAGUCHI K, ZAMBRANO N, SAKAMOTO H, APPELLA E AND GRONENBORN AM. (1994). High-resolution solution structure of the oligomerization domain of p53 by multi-dimensional NMR. Science, 265, 386-391.
15. DILLER L, KASSEL J, NELSON CE, GRYKA MA, LITWAK G, GEBHARDT M, BRESSAC B, OZTURK M, BAKER SJ, VOGELSTEIN B AND ET AL. (1990). p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell Biol., 10, 5772-5781.
16. DITTMER D, PATI S, ZAMBETTI G, CHU S, TERESKY AK, MOORE M, FINLAY C AND LEVINE AJ. (1993). Gain of function mutations in p53. Nature Genet., 4, 42-46.
17. DUMAZ N, STARY A, SOUSSI T, DAYA-GROSJEAN L AND SARASIN A. (1994). Can we predict solar ultraviolet radiation as the causal event in human tumours by analysing the mutation spectra of the p53 gene? Mutat. Res., 307, 375-386.
18. ELIYAHU D, MICHAMOVITZ D, ELIYAHU S, PINHASI-KIMHI O AND OREN M. (1989). Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl Acad. Sci. USA, 86, 8763-8767.
19. EVANS MK, TAFFE BG, HARRIS CC AND BOHR VA. (1993). DNA strand bias in the repair of the p53 gene in normal human and xeroderma pigmentosum group C fibroblasts. Cancer Res., 53, 5377-5381.
20. FEITELSON MA, ZHU M, DUAN LX AND LONDON WT. (1993). Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8, 1109-1117.
21. FIELDS S AND JANG SK. (1990). Presence of a potent transcription activating sequence in the p53 protein. Science, 249, 1046-1048.
22. FINLAY CA, HINDS PW AND LEVINE AJ. (1989). The p53 protooncogene can act as a suppressor of transformation. Cell, 57, 1083-1093.
23. FORRESTER K, LUPOLD SE, OTT VL, CHAY CH, BAND V, WANG XW AND HARRIS CC. (1995). Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene, 10, 2103-2111.
24. GREENBLATT MS, BENNETT WP, HOLLSTEIN M AND HARRIS CC. (1994). Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878.
25. HARRIS CC. (1991). Chemical and physical carcinogenesis: advances and perspectives. Cancer Res., 51, 5023s-5044s.
26. HARRIS CC. (1993). p53: at the crossroads of molecular carcinogenesis and cancer risk assessment. Science, 262, 1980-1981.
27. HARRIS CC AND HOLLSTEIN M. (1993). Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329, 1318-1327.
28. HERMAN JG, LATIF F, WENG Y, LERMAN MI, ZBAR B, LIU S, SAMID D, DUAN DS, GNARRA JR, LINEHAN WM AND BAYLIN SB. (1994). Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA, 91, 9700-9704.
29. HINO O, NOMURA K, OHTAKE K, KAWAGUCHI T, SUGANO H AND KITAGAWA T. (1989). Instability of integrated hepatitis B virus DNA with inverted repeat structure in a transgenic mouse. Cancer Genet. Cytogenet., 37, 273-278.
30. HINO O, TABATA S AND HOTTA Y. (1991). Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. Proc. Natl Acad. Sci. USA, 88, 9248-9252.
31. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B AND HARRIS CC. (1991). p53 mutations in human cancers. Science, 253, 49-53.
32. HOLLSTEIN M, RICE K, GREENBLATT MS, SOUSSI T, FUCHS R, SORLIE T, HOVIG E, SMITH-SORENSEN B, MONTESANO R AND HARRIS CC. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucl. Acids Res., 22, 3547-3551.
33. HSIAO M, LOW J, DORN E, KU D, PATTENGALE P, YEARGIN J AND HAAS M. (1994). Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am. J. Pathol., 145, 702-714.
34. HSU IC, METCALF RA, SUN T, WELSH JA, WANG NJ AND HARRIS CC. (1991). Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature, 350, 427-428.
35. HUPP TR AND LANE DP. (1995). Allosteric activation of latent p53 tetramers. Curr. Biol., 4, 865-875.
36. JAYARAMAN L AND PRIVES C. (1995). Activation of p53 sequence specific DNA binding by short single strands of DNA requires the p53 C-termius. Cell, 81, 1021-1029.
37. JEFFREY PD, GORINA S AND PAVLETICH NP. (1995). Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science, 267, 1498-1502.
38. JEGO N, THOMAS G AND HAMELIN R. (1993). Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers. Oncogene, 8, 209.
39. KEKULË AS, LAUER U, MEYER M, CASELMANN WH, HOFSCHNEIDER PH AND KOSHY R. (1990). The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature, 343, 457-461.
40. KRAWCZAK M AND COOPER DN. (1991). Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Hum. Genet., 86, 425-441.
41. KUNKEL TA. (1993). Nucleotide repeats. Slippery DNA and diseases. Nature, 365, 207-208.
42. LANE DP AND BENCHIMOL S. (1990). p53: oncogene or anti-oncogene. Genes Dev., 4, 1-8.
43. LEE W, HARVEY TS, YIN Y, YAU P, LITCHFIELD D AND ARROW-SMITH CH. (1994). Solution structure of the tetrameric minimum transforming domain of p53. Nature Struc. Biol., 1, 877-890.
44. LEVINE AJ, MOMAND J AND FINLAY CA. (1991). The p53 tumour suppressor gene. Nature, 351, 453-456.
45. LEVINE AJ, PERRY ME, CHANG A, SILVER A, DITTMER D, WU M AND WELSH D. (1994). The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br. J. Cancer, 69, 409-416.
46. LI D, CAO Y, HE L, WANG NJ AND GU J. (1993). Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis, 14, 169-173.
47. LI FP, GARBER JE, FRIEND SH, STRONG LC, PATENAUDE AF, JUENGST ET, REILLY PR, CORREA P AND FRAUMENI JF, JR. (1992). Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J. Natl Cancer Inst., 84, 1156-1160.
48. LIN J, CHEN J, ELENBAAS B AND LEVINE AJ. (1994). Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev., 8, 1235-1246.
49. LIU X, MILLER CW, KOEFFLER PH AND BERK AJ. (1993). The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol. Cell Biol., 13, 3291-3300.
50. LU H AND LEVINE AJ. (1995). Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl Acad. Sci. USA, 92, 5154-5158.
51. MACK DH, VARTIKAR J, PIPAS JM AND LAIMINS LA. (1993). Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature, 363, 281-283.
52. MAGUIRE HF, HOEFFLER JP AND SIDDIQUI A. (1991). HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science, 252, 842-844.
53. MARTIN DW, MUNOZ RM, SUBLER MA AND DEB S. (1993). p53 binds to the TATA-binding protein-TATA complex. J. Biol. Chem., 268, 13062-13067.
54. MERCER WE, SHIELDS MT, AMIN M, SAUVE GJ, APPELLA E, ROMANO JW AND ULLRICH SJ. (1990). Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc. Natl Acad. Sci. USA, 87, 6166-6170.
55. NATIONAL RESEARCH COUNCIL. (1994). Assessment of Toxicology. In Science and Judgement in Risk Assessment, National Academy of Sciences (ed.) pp. 56-67. National Academy Press: Washington, DC.
56. NGUYEN T, BRUNSON D, CRESPI CL, PENMAN BW, WISHNOK JS AND TANNENBAUM SR. (1992). DNA damage and mutation in human cells exposed to nitric oxide in vitro. Biochemistry, 285, 1173-1180.
57. PARK M AND VANDE WOUDE GF. (1989). Principles of molecular cell biology of cancer: oncogenes. In Cancer: Principles & Practice of Oncology. 3rd edn, DeVita VT, Jr., Hellman S and Rosenberg SA. (eds) pp. 45-66. JB Lippincott: New York.
58. PATERLINI P, POUSSIN K, KEW M, FRANCO D AND BRECHOT C. (1995). Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology, 21, 313-321.
59. PERERA FP AND SANTELLA R. (1993). Carcinogenesis. In Molecular Epidemiology: Principles and Practices, Schulte P and Perera FP. (eds) pp. 277-300. Academic Press: New York.
60. PONCHEL F, PUISIEUX A, TABONE E, MICHOT JP, FROSCHL G, MOREL AP, FREBOURG T, FONTANIERE B, OBERHAMMER F AND OZTURK M. (1994). Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res., 54, 2064-2068.
61. PRIVES C. (1994). How loops, beta sheets, and alpha helices help us to understand p53. Cell, 78, 543-546.
62. RAYCROFT L, WU H AND LOZANO G. (1990). Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science, 249, 1049-1051.
63. RIPLEY LS. (1990). Frameshift mutation: determinants of specificity. Annu. Rev Genet., 24, 189-213.
64. SAVITSKY K, BAR-SHIRA A, GILAD S, ROTMAN G, ZIV Y, VANAGAITE L, TAGLE DA, SMITH S, UZIEL T, SFEZ S, ASHKENAZI M, PECKER I, FRYDMAN M, HARNIK R, PATANJALI SR, SIMMONS A, CLINES GA, SARTIEL A, GATTI RA, CHESSA L, SANAI O, LAVIN MF, JASPERS NG, MALCOLM A, TAYLOR R, ARLETT CF, MIKI T, WEISSMAN SM, LOVETT M, COLLINS FS AND SHILOH Y. (1995). A single Ataxia-Telangiectasia gene with a product similar to Pi-3 kinase. Science, 268, 1749-1753.
65. SCORSONE KA, ZHOU YZ, BUTEL JS AND SLAGLE BL. (1992). p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res., 52, 1635-1638.
66. SETO E, USHEVA A, ZAMBETTI GP, MOMAND J, HORIKOSHI N, WEINMANN R, LEVINE AJ AND SHENK T. (1992). Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 89, 12028-12032.
67. SHIELDS PG AND HARRIS CC. (1991). Molecular epidemiology and the genetics of environmental cancer. JAMA, 266, 681-687.
68. SHIRAKATA Y, KAWADA M, FUJIKI Y, SANO H, ODA M, YAGINUMA K, KOBAYASHI M AND KOIKE K. (1989). The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells. Jpn. J. Cancer Res., 80, 617-621.
69. SOUSSI T, CARON DE FROMENTEL C AND MAY P. (1990). Structural aspects of the p53 protein in relation to gene evolution. Oncogene, 5, 945-952.
70. SOUSSI T, LEGROS Y, LUBIN R, ORY K AND SCHLICHTHOLZ B. (1994). Multifactorial analysis of p53 alteration in human cancer: a review. Int. J. Cancer, 57, 1-9.
71. SPANDAU DF AND LEE CH. (1988). Trans-activation of viral enhancers by the hepatitis B virus X protein. J. Virol., 62, 427-434.
72. THUT CJ, CHEN J-L, KLEMM R AND TJIAN R. (1995). p53 transcriptional activation mediated by coactivators TAFii40 and TAFii60. Science, 267, 100-104.
73. TORNALETTI S AND PFEIFER GP. (1994). Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer. Science, 263, 1436-1438.
74. TRUANT R, XIAO H, INGLES CJ AND GREENBLATT J. (1993). Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. J. Biol. Chem., 268, 2284-2287.
75. TWU JS AND SCHLOEMER RH.. (1987). Transcriptional transactivating function of hepatitis B virus. J. Virol., 61, 3448-3453.
76. UEDA H, ULLRICH SJ, GANGEMI JD, KAPPEL CA, NGO L, FEITELSON MA AND JAY G. (1995). Functional inactivation but not structural mutation of p53 causes liver cancer. Nature Genet., 9, 41-47.
77. UNSAL H, YAKICIER C, MARCAIS C, KEW M, VOLKMANN M, ZENTGRAF H, ISSELBACHER KJ AND OZTURK M. (1994). Genetic heterogeneity of hepatocellular carcinoma. Proc. Natl Acad. Sci USA, 91, 822-826.
78. VOGELSTEIN B AND KINZLER KW. (1992a). p53 function and dysfunction. Cell, 70, 523-526.
79. VOGELSTEIN B AND KINZLER KW. (1992b). Carcinogens leave fingerprints. Nature, 355, 209-210.
80. WANG XW, FORRESTER K, YEH H, FEITELSON MA, GU JR AND HARRIS CC. (1994). Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity and association with transcription factor ERCC3. Proc. Natl Acad. Sci. USA, 91, 2230-2234.
81. WANG XW, YEH H, SCHAEFFER L, ROY R, MONCOLLIN V, EGLY JM, WANG Z, FRIEDBERG EC, EVANS MK, TAFFE BG, BOHR VA, HOEIJMAKERS JH, FORRESTER K AND HARRIS CC. (1995). p53 Modulation of TFIIH-associated nucleotide excision repair activity. Nature Genet., 10, 188-195.
82. WANG XW, GIBSON MK, VERMEULEN W, YEH H. FORRESTER K, STURZBACHER H-W, HOEIJMAKERS JHJ AND HARRIS CC. (1995). Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res. (in press).
83. WINK DA, KASPRZAK KS, MARAGOS CM, ELESPURU RK, MISRA M, DUNAMS TM, CEBULA TA, KOCH WH, ANDREWS AW, ALLEN JS AND ET AL. (1991). DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science, 254, 1001-1003.
84. ZIEGLER A, JONASON AS, LEFFELL DJ, SIMON JA, SHARMA HW, KIMMELMAN J, REMINGTON L, JACKS T AND BRASH DE. (1994). Sunburn and p53 in the onset of skin cancer. Nature, 372, 773-776.